Rice University researchers have developed compact CRISPR enzymes capable of editing DNA sites that earlier versions struggled to reach, demonstrating the approach in two genes associated with coronary heart disease risk.
The research, published in Nature Communications, used professor Han Xiao’s AI-supported Sequence Display technology to evolve variants of SlugCas9, a compact gene-editing enzyme.
CRISPR enzymes must recognize a short DNA sequence known as a protospacer adjacent motif, or PAM, before editing a nearby target. Although an enzyme may recognize several PAMs, weak binding at particular sites can limit its usefulness for specific genetic changes.
The Rice team focused on four PAMs that SlugCas9 recognized inefficiently. Using Sequence Display, researchers identified promising enzyme candidates within a week and developed variants better suited to those sites.
In cultured cells, the evolved enzymes edited targeted locations in APOC3 and PCSK9, genes linked to coronary heart disease risk. The edits introduced potentially protective genetic changes associated with lower disease risk.
The findings represent a proof of concept in cultured cells rather than a demonstrated treatment. Their significance lies in expanding access to genetic sites that were previously difficult to edit with the compact enzyme.
Sequence Display generates large datasets that artificial intelligence can use to identify protein sequences suited to particular functions. In this study, the approach supported the development of Cas9 variants with improved activity at selected DNA targets.
Xiao, a professor of chemistry and director of Rice’s SynthX Center, served as corresponding author. Graduate student Linqi Cheng was the paper’s first author.
Funding came from sources including the National Institutes of Health, U.S. Department of Defense, Robert A. Welch Foundation and Rice research programs.
KEY QUOTES
“We cannot easily or precisely change the PAMs in a given gene. But with Sequence Display technology, we could quickly evolve a Cas9 enzyme that would better recognize the PAMs already present in the gene.”
Linqi Cheng, Graduate Student At Rice University And First Author Of The Study
“The specific sites we wanted to edit in APOC3 and PCSK9 had the PAMs that prior versions of SlugCas9 couldn’t reliably bind to. With our evolved SlugCas9, we were able to easily and precisely edit these sites in cultured cells, introducing potentially protective genetic changes linked to a lower risk of coronary heart disease, unlocking the power and possibility of CRISPR.”
Linqi Cheng, Graduate Student At Rice University And First Author Of The Study

